57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG

Key Points

• Deutsche Bank acquired 57,784 shares of Stoke Therapeutics in the second quarter, worth approximately $1.89 million and representing a 0.09% stake. Several other investment firms also initiated or increased positions.
• Stoke reported a quarterly loss of $0.93 per share, missing analyst expectations of $0.80, though revenue of $9.32 million exceeded the $4.89 million consensus estimate. Insiders sold 30,623 shares worth about $953,765 during the last quarter.
• Wall Street remains broadly positive, with 10 analysts rating the stock a Buy and one rating it a Sell. The consensus rating is Moderate Buy, with an average price target of $44.25 versus the reported share price of $31.62.

Deutsche Bank AG acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 57,784 shares of the company's stock, valued at approximately $1,891,000. Deutsche Bank AG owned 0.09% of Stoke Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of STOK. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $26,000. KBC Group NV bought a new stake in shares of Stoke Therapeutics in the 1st quarter valued at $36,000. Harbour Investments Inc. raised its stake in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after buying an additional 898 shares during the period. Western Wealth Management LLC acquired a new stake in Stoke Therapeutics during the 1st quarter worth $55,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company's stock worth $60,000 after acquiring an additional 1,215 shares in the last quarter.

Insider Activity

In related news, insider Barry Ticho sold 7,176 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the completion of the transaction, the insider directly owned 20,422 shares of the company's stock, valued at approximately $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 2,861 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel owned 21,225 shares of the company's stock, valued at approximately $679,836.75. This represents a 11.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 30,623 shares of company stock worth $953,765 in the last quarter. Corporate insiders own 9.60% of the company's stock.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $31.62 on Friday. Stoke Therapeutics, Inc. has a one year low of $18.80 and a one year high of $40.22. The stock's 50-day moving average is $31.22 and its 200-day moving average is $32.26. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -9.47 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, equities analysts expect that Stoke Therapeutics, Inc. will post -3.52 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on STOK. JPMorgan Chase & Co. began coverage on Stoke Therapeutics in a research note on Friday, August 21st. They issued an "overweight" rating and a $40.00 target price for the company. Chardan Capital reiterated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th. BTIG Research reiterated a "buy" rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. Canaccord Genuity Group lowered their target price on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. Finally, Wedbush increased their target price on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Stoke Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source